Parents type “Ozempic for kids” into search bars. The drug they are asking about is semaglutide, and the clinical trial they need to understand is STEP Young.
In September, Novo Nordisk announced that 40.4% of children aged 6 to under 12 receiving once-weekly semaglutide alongside diet and exercise counseling were no longer classified as having obesity after 68 weeks. In the placebo group, the corresponding figure was 0%.
That is an important result, particularly because most children entering the trial had severe obesity. But the number comes from a company announcement using a specific statistical analysis, and it does not tell us how much the children’s average body mass index actually changed.
Novo says the trial met its primary endpoint. It has not yet publicly provided the full effect size, confidence intervals or adverse-event tables. Those details are scheduled for an oral presentation at ObesityWeek on November 16, 2026, alongside a simultaneous publication.
The distinction matters. A positive company announcement can establish that a clinical trial met a predefined objective. It cannot replace the detailed evidence doctors and families need when considering treatment for children who are still growing.
What the STEP Young Phase 3 Trial Actually Tested
According to Novo Nordisk’s September 7 announcement, STEP Young is a randomized, double-blind, placebo-controlled, multinational Phase 3 study involving 165 children aged 6 to under 12 with obesity.
More than 85% of participants had class II or class III obesity at baseline, the more severe categories of pediatric obesity. That makes the study population substantially different from a general sample of children who happen to be above average weight.
Children assigned to the active-treatment group received once-weekly subcutaneous semaglutide, with a maximum dose of either 1.7 mg or 2.4 mg depending on body weight at enrollment. Those assigned to the control group received placebo injections.
Both groups also participated in lifestyle modification involving a reduced-calorie diet and increased physical activity. The trial therefore tested semaglutide added to lifestyle intervention, not medication as a replacement for those measures.
The primary endpoint was percentage change in body mass index, or BMI, from baseline to week 68. A confirmatory secondary endpoint examined whether participants moved into a lower BMI classification. Additional outcomes involving body measurements, metabolic risk factors and body composition were scheduled for assessment at weeks 68 and 104.
The study is registered as NCT05726227 and was conducted to address regulatory post-marketing study requirements associated with semaglutide’s clinical development program.
This distinction is important for the language surrounding the study. Although many families recognize the name Ozempic, the investigated regimen uses injectable semaglutide at doses associated with Wegovy’s weight-management development program.
Ozempic and Wegovy contain the same active molecule, but they are separate branded medicines with different approved uses. The STEP Young trial does not establish a pediatric obesity indication for Ozempic.
What the 40.4% Result Means, and What It Doesn’t
The most widely reported STEP Young figure is that 40.4% of children receiving semaglutide were below the obesity BMI threshold at week 68, compared with none of those receiving placebo.
In children, obesity is defined using age- and sex-specific BMI growth charts rather than the fixed BMI thresholds commonly applied to adults. Under the CDC classification used by the study, obesity generally begins at the 95th percentile for age and sex.
Falling below that threshold does not necessarily mean reaching a normal-weight category. A child who moves from obesity into the overweight category is included in the reported figure.
That remains a clinically relevant change in classification, but it is different from claiming that 40% of children achieved normal body weight or that their obesity-related health risks disappeared.
The percentage also comes with a technical qualification. Novo calculated it using the trial-product estimand, which estimates the treatment effect under a hypothetical scenario in which participants adhere to their assigned treatment.
This is a recognized statistical approach, but it answers a different question from a treatment-policy estimand, which evaluates the effect of assignment to treatment regardless of whether participants discontinue medication or require other treatment.
Neither method is automatically invalid or inherently misleading. They estimate different aspects of treatment effectiveness. Without seeing both results, however, readers cannot determine how sensitive the reported benefit is to treatment discontinuation and adherence.
The biggest missing number is the actual mean percentage change in BMI.
Novo confirmed that the primary endpoint was met, indicating greater BMI reduction with semaglutide than placebo. But the September announcement did not disclose the magnitude of that difference, its confidence interval or the detailed statistical results.
Those omissions do not negate the finding. They limit how confidently outsiders can evaluate its size, precision and clinical implications.
Four in ten children crossed below the obesity threshold in Novo’s analysis. How much BMI changed, and how consistently that benefit was maintained, remain essential questions.
Safety Questions Go Beyond Nausea
When obesity medicines are studied in adults, gastrointestinal symptoms often dominate the safety discussion. Nausea, vomiting, diarrhea and constipation are familiar adverse effects of GLP-1 receptor agonists.
In children aged 6 to 11, the questions extend further.
Children are growing, developing bone and muscle, and approaching or entering puberty. A medicine that reduces appetite and changes food intake raises legitimate questions about nutrition, growth trajectories and longer-term physical development.
Novo said the overall safety and tolerability profile observed in STEP Young was consistent with previous pediatric and adult trials involving semaglutide and liraglutide. The company also reported that no new safety concerns were identified involving growth or pubertal development.
That is an encouraging preliminary statement. It is not the same as publishing the measurements and adverse-event data needed to independently evaluate those conclusions.
The September announcement did not provide detailed counts for gastrointestinal events, serious adverse events, treatment discontinuations or growth-related outcomes. Nor did it provide the full dataset needed to evaluate differences across the study’s age range.
Some questions may also extend beyond the duration of the trial. Pubertal development occurs over several years, and a study involving 165 participants cannot reliably detect every uncommon or delayed safety outcome.
The trial’s supportive assessments through week 104 may add useful evidence, but the public announcement does not establish that complete 104-week results will accompany the November presentation.
The distinction between detecting no new safety signal and proving long-term safety should remain central to how these findings are reported.
For a pediatric medicine, the adverse-event tables are not secondary details. They are part of the evidence needed to judge whether the benefit is acceptable.
Where Ozempic and Wegovy Stand for Children
The positive STEP Young announcement does not change which medicines are currently authorized for pediatric obesity treatment in the United States.
Injectable Wegovy, which contains semaglutide, has an FDA-approved weight-management indication for adolescents aged 12 and older with obesity. Ozempic, although it contains the same active molecule, is marketed for different indications and should not be treated as an interchangeable pediatric obesity product.
As of November 6, 2026, semaglutide injection remains investigational for obesity treatment in children younger than 12. No GLP-1 receptor agonist has an FDA-approved indication for common pediatric obesity in that age group.
That does not mean all care options disappear before a child’s twelfth birthday. Family-based behavioral treatment, nutritional support, evaluation for obesity-related complications and specialist care remain important parts of management. Rare genetic or syndromic forms of obesity may also involve different treatment considerations.
But families whose children have severe obesity face real treatment challenges, particularly where access to intensive multidisciplinary care is limited.
That is why a randomized Phase 3 trial in younger children matters. It provides evidence regulators may consider when reviewing whether the benefits and risks support an additional approved indication.
A trial meeting its primary endpoint does not automatically produce regulatory authorization. Authorities must review the full efficacy results, safety findings, manufacturing information and proposed labeling before making a decision.
Novo’s September announcement did not establish a timeline for a U.S. application or approval decision for children under 12.
Until that changes, the STEP Young results should be understood as evidence supporting a potential future treatment option, not as permission to treat young children with an existing adult or adolescent prescription regimen.
What the Earlier Liraglutide Trial Can Tell Us
STEP Young is not the first randomized trial of a GLP-1 medicine in children younger than 12.
In September 2024, researchers published results from the SCALE Kids trial of liraglutide, another Novo Nordisk GLP-1 receptor agonist, in the New England Journal of Medicine.
That study randomized 82 children aged 6 to under 12 with obesity to receive once-daily liraglutide or placebo, alongside lifestyle intervention, over a 56-week treatment period.
Mean BMI decreased by 5.8% in the liraglutide group and increased by 1.6% in the placebo group, an estimated difference of 7.4 percentage points.
At least a 5% reduction in BMI occurred in 46% of participants receiving liraglutide, compared with 9% receiving placebo.
The safety data provide a useful reminder of why the full STEP Young results matter. Gastrointestinal adverse events were reported in 80% of children receiving liraglutide versus 54% on placebo. Serious adverse events occurred in 12% and 8%, respectively.
Those results demonstrate that GLP-1 therapy can produce measurable BMI changes in younger children, while also producing adverse effects that deserve careful consideration.
They cannot establish whether semaglutide is more effective, safer or easier to tolerate. The studies involve different medicines, dosing schedules, participant populations and treatment durations.
The comparison is further limited because STEP Young’s full primary outcome and safety details are not yet public. A meaningful evaluation should examine both studies’ definitions, analyses and follow-up periods rather than comparing isolated headline percentages.
For readers interested in the molecule itself, Grey Pepper has previously explained why semaglutide lasts approximately one week while natural GLP-1 is cleared within minutes.
That longer duration helps explain once-weekly dosing, but it does not settle the questions of long-term safety, growth or treatment persistence in children.
What November 16 Must Show
Novo Nordisk has scheduled the STEP Young oral presentation for Monday, November 16, during the 10:00–11:30 a.m. Eastern Time session at ObesityWeek 2026 in Washington, D.C.
The company’s October 29 conference preview also announced a simultaneous publication of the full findings.
Several details will determine how the September announcement should ultimately be interpreted.
First is the primary endpoint: the actual mean percentage change in BMI for the semaglutide and placebo groups, along with the estimated treatment difference and confidence interval. This is the central measurement that has not yet been publicly quantified.
Second is the treatment-policy analysis. Readers need to understand how outcomes differed when the analysis accounts for treatment discontinuations and other events that occur in a real trial. It will be especially important to distinguish estimated outcomes under full adherence from results reflecting the experience of all randomized participants.
Third is the complete safety record. Rates of nausea, vomiting, other gastrointestinal symptoms, serious adverse events and treatment discontinuations should be examined alongside measurements of growth and pubertal development.
Fourth is the longer-term evidence. Week-104 assessments are part of the study design, but their availability and completeness should be checked rather than assumed. Additional follow-up will matter because childhood growth and treatment decisions continue well beyond the primary 68-week assessment.
There is also a question STEP Young may not fully answer: what happens after treatment stops.
In adult obesity trials, stopping GLP-1 treatment has often been followed by substantial weight regain. Whether the same patterns occur in younger children, how subsequent development affects those outcomes and how families might manage long-term treatment are questions requiring further research.
Children beginning treatment at age 6 or 7 have many years of growth and development ahead of them. A 68-week clinical endpoint can help establish short-term efficacy, but it cannot map every medical decision that may follow through adolescence.
A clinical trial can show what a medicine does over 68 weeks. Families and physicians must consider what those findings mean over the course of childhood.
STEP Young could become an important source of evidence for treating severe obesity in children younger than 12. Its topline finding is notable, particularly in a population where most participants entered with class II or III obesity.
But the public record remains incomplete. The 40.4% result is a company-reported estimate from one statistical approach, not a substitute for the primary BMI outcome, detailed safety results or longer-term follow-up.
For now, the appropriate conclusion is that semaglutide showed a promising benefit in a randomized pediatric trial, while its overall benefit-risk profile in this age group still requires fuller evaluation.
That is what November 16 should begin to clarify.
The headline belongs to the 40.4% finding. The medical judgment belongs to the complete dataset.
Related on Grey Pepper: Why Semaglutide Lasts a Week and Lotte Bjerre Knudsen’s Role in Developing Long-Acting GLP-1 Medicines.
Sources and Further Reading
- Novo Nordisk: STEP Young Phase 3 Topline Results, September 7, 2026.
- Novo Nordisk: ObesityWeek 2026 Presentation Schedule and Planned STEP Young Publication, October 29, 2026.
- ClinicalTrials.gov: STEP Young Trial Registration, NCT05726227.
- Patient Care: Semaglutide Improves BMI Category in Pediatric Phase 3 Trial, September 7, 2026.
- Fox CK, et al. Liraglutide for Children 6 to Under 12 Years of Age With Obesity — A Randomized Trial. New England Journal of Medicine.
- U.S. Food and Drug Administration: Approved Wegovy and Ozempic Indications and Safety Context, September 2025.
- Centers for Disease Control and Prevention: Child and Teen BMI Categories.
- Life Science Daily: ObesityWeek 2026 Preview, November 3, 2026.
